Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Metrics to compare | 603590 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship603590PeersSector | |
---|---|---|---|---|
P/E Ratio | 201.0x | 31.1x | −0.5x | |
PEG Ratio | −2.74 | −0.16 | 0.00 | |
Price/Book | 2.9x | 3.2x | 2.6x | |
Price / LTM Sales | 10.8x | 4.8x | 3.3x | |
Upside (Analyst Target) | −22.7% | 10.6% | 40.1% | |
Fair Value Upside | Unlock | 2.8% | 5.1% | Unlock |